# Actuate Therapeutics, Inc.

**ACTU**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001652935

# None

**No letter**

4 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $14.0M |
| **Warnings** | short runway, thin data<br>not computable: degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Mar 26, 2026<br>233 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026 |
| **Last close** | $0.29<br>2026-11-13; market equity $17.4M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 26, 2026*

company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 ("GSK-3"). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta ("GSK-3?"), a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3? signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 16.4** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (25.9%) | (6.6%) | 16.4 | 799 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 76.2** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (41.61) | (0.31) | 86.5 | 743 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 2.39x | 2.96x | 65.9 | 825 | 2025-12-31 |
| **Growth and financing, sleeve percentile 61.5** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | |
| *four consecutive annual FCF observations are required; found 0* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | not computable | 2.3% | | | |
| *four annual observations are required; found 2* | | | | | |
| Net share issuance, one year | 21.4% | 2.4% | 61.5 | 627 | 2026-03-25 |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 1.6 months |
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (88.3%) | (1.5%) | 3 |
| Distance from 52-week high | (96.3%) | (32.0%) | 1 |
| EBIT to enterprise value | not computable | (1.8%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | (0.05) | 0.29 | 8 |
| Sales to price | not computable | 0.29 | |
| Composite equity issuance, five years | not computable | 19.1% | |
| Relative strength against the sector, log excess return | (2.31) | (0.18) | 3 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $2.1M |
| Operating cash flow, four quarters | -$16.1M |
| Months of runway | 1.6 |
| Days since last periodic filing | 1 (10-Q received Nov 13, 2026) |
| Median daily dollar volume, 63 sessions | $202,541 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$22.2M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$19.2M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 3 | assets | us-gaap:Assets | $14.0M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 4 | assets | us-gaap:Assets | $9.3M | 2024-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 5 | current assets | us-gaap:AssetsCurrent | $13.6M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $5.7M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$154.6M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$22.5M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 9 | book equity | us-gaap:StockholdersEquity | $7.9M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 10 | liabilities | us-gaap:Liabilities | $6.1M | 2025-12-31 | 2026-03-26 | 10-K | 26-002257 |
| 11 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 23,709,943 | 2026-03-25 | 2026-03-26 | 10-K | 26-002257 |
| 12 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 19,531,636 | 2025-03-10 | 2025-03-13 | 10-K | 25-001581 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.